These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35232774)

  • 1. Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.
    Xu C; Smith ER; Tiong MK; Ruderman I; Toussaint ND
    J Am Soc Nephrol; 2022 May; 33(5):1011-1032. PubMed ID: 35232774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review.
    Pluquet M; Kamel S; Choukroun G; Liabeuf S; Laville SM
    Toxins (Basel); 2022 Sep; 14(9):. PubMed ID: 36136575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications.
    Bover J; Ureña-Torres P; Górriz JL; Lloret MJ; da Silva I; Ruiz-García C; Chang P; Rodríguez M; Ballarín J
    Nefrologia; 2016; 36(6):597-608. PubMed ID: 27595517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
    Lioufas NM; Pascoe EM; Hawley CM; Elder GJ; Badve SV; Block GA; Johnson DW; Toussaint ND
    J Am Soc Nephrol; 2022 Jan; 33(1):59-76. PubMed ID: 34645696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
    Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia.
    Kaesler N; Goettsch C; Weis D; Schurgers L; Hellmann B; Floege J; Kramann R
    Nephrol Dial Transplant; 2020 Jan; 35(1):65-73. PubMed ID: 30715488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for chronic kidney disease-associated restless legs syndrome.
    Gopaluni S; Sherif M; Ahmadouk NA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD010690. PubMed ID: 27819409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet agents for chronic kidney disease.
    Natale P; Palmer SC; Saglimbene VM; Ruospo M; Razavian M; Craig JC; Jardine MJ; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD008834. PubMed ID: 35224730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
    Witham MD; Lees JS; White M; Band M; Bell S; Chantler DJ; Ford I; Fulton RL; Kennedy G; Littleford RC; McCrea IV; McGlynn D; Panarelli M; Ralston MR; Rutherford E; Severn A; Thomson N; Traynor JP; Struthers AD; Wetherall K; Mark PB
    J Am Soc Nephrol; 2020 Oct; 31(10):2434-2445. PubMed ID: 32817311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
    PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD).
    Bressendorff I; Hansen D; Schou M; Kragelund C; Svensson M; Hashemi B; Kristensen T; Vrist MH; Borg R; Tougaard B; Borg K; Hjortkjær HØ; Kristiansen CH; Carlson N; Nasiri M; Ashraf H; Pasch A; Brandi L
    J Am Soc Nephrol; 2023 May; 34(5):886-894. PubMed ID: 36749131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
    Vermeulen EA; Eelderink C; Hoekstra T; van Ballegooijen AJ; Raijmakers P; Beulens JW; de Borst MH; Vervloet MG
    Trials; 2022 Sep; 23(1):769. PubMed ID: 36096824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.